SkyAI (SKYA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Sep, 2026Executive summary
Special Committee of independent directors reviewed and rejected Forward Industries' all-stock acquisition proposal, determining it was not in shareholders' best interests.
Board reaffirms commitment to Solana DAT strategy, holding over two million SOL with no debt and generating significant staking revenue.
From August 2025 to June 2026, recognized over $12 million in staking revenue and held $12.1 million in cash and stablecoins as of June 30, 2026.
Solana validator generated an annualized gross yield of 6.01% in SOL, outperforming the network average.
Board and management remain focused on unlocking long-term value for shareholders.
Voting matters and shareholder proposals
Shareholders are asked to vote for all director nominees and the 2026 Equity Incentive Plan at the Annual Meeting on September 18, 2026.
Board unanimously recommends voting FOR each nominee and the equity plan.
Board of directors and corporate governance
Board emphasizes strong governance, transparency, and oversight, including public disclosure of consultant and advisor relationships.
Special Committee of independent directors evaluated the acquisition proposal with independent advisors.
Board will continue to evaluate governance practices as the company evolves.
Latest events from SkyAI
- Shareholders will vote on director elections, auditor ratification, and a new equity incentive plan.SKYA
Proxy filing - $109.5M H1 net loss, Solana losses, rebrand, and new CFO amid AI finance platform pivot.SKYA
Q2 2026 - Q1 2026 net loss was $86.2M, driven by large SOL losses and modest product and staking revenue.SKYA
Q1 2026 - 2025 saw a $282.5M net loss amid a shift to a SOL treasury strategy and major capital raise.SKYA
Q4 2025 - Hybrid medical device and SOL treasury strategy, with major warrant-driven capital raise.SKYA
Registration Filing - Dual medical device and SOL treasury strategy with $1B shelf, high risk and regulatory exposure.SKYA
Registration Filing - First revenues, $50M U.S. deal, and expansion into high-margin prefilled syringes drive growth.SKYA
Life Sciences Virtual Investor Forum - $50M U.S. contract drives facility expansion and early revenue, with profitability targeted for 2025.SKYA
Aegis Capital Financial Conference - Stockholders considered a reverse split, warrant issuance, and adjournment, with quorum met.SKYA
Status Update